The stock price of Biolife Solutions Inc (NASDAQ: BLFS) has jumped by 4.76 compared to previous close of 15.14. Despite this, the company has seen a fall of -7.25% in its stock price over the last five trading days. PRNewsWire reported 2024-03-04 that BOTHELL, Wash., March 4, 2024 /PRNewswire/ — BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies (“CGT”) and broader biopharma markets, today announced that Roderick de Greef, Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences.
Is It Worth Investing in Biolife Solutions Inc (NASDAQ: BLFS) Right Now?
The 36-month beta value for BLFS is at 1.73. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BLFS is 43.15M, and currently, shorts hold a 7.41% of that float. The average trading volume for BLFS on April 19, 2024 was 369.57K shares.
BLFS’s Market Performance
BLFS stock saw a decrease of -7.25% in the past week, with a monthly decline of -10.09% and a quarterly a decrease of -6.87%. The volatility ratio for the week is 8.10%, and the volatility levels for the last 30 days are 5.46% for Biolife Solutions Inc (BLFS). The simple moving average for the past 20 days is -9.19% for BLFS’s stock, with a 2.86% simple moving average for the past 200 days.
Analysts’ Opinion of BLFS
Many brokerage firms have already submitted their reports for BLFS stocks, with Jefferies repeating the rating for BLFS by listing it as a “Buy.” The predicted price for BLFS in the upcoming period, according to Jefferies is $22 based on the research report published on April 04, 2024 of the current year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see BLFS reach a price target of $29. The rating they have provided for BLFS stocks is “Buy” according to the report published on July 11th, 2023.
Oppenheimer gave a rating of “Outperform” to BLFS, setting the target price at $28 in the report published on April 25th of the previous year.
BLFS Trading at -9.63% from the 50-Day Moving Average
After a stumble in the market that brought BLFS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.27% of loss for the given period.
Volatility was left at 5.46%, however, over the last 30 days, the volatility rate increased by 8.10%, as shares sank -11.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.33% lower at present.
During the last 5 trading sessions, BLFS fell by -7.25%, which changed the moving average for the period of 200-days by -26.23% in comparison to the 20-day moving average, which settled at $17.36. In addition, Biolife Solutions Inc saw -2.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BLFS starting from Berard Todd, who sale 10,000 shares at the price of $15.67 back on Apr 15 ’24. After this action, Berard Todd now owns 129,644 shares of Biolife Solutions Inc, valued at $156,700 using the latest closing price.
Aebersold Sarah, the Chief Human Resources Officer of Biolife Solutions Inc, sale 4,000 shares at $17.65 during a trade that took place back on Apr 01 ’24, which means that Aebersold Sarah is holding 65,843 shares at $70,600 based on the most recent closing price.
Stock Fundamentals for BLFS
Current profitability levels for the company are sitting at:
- -0.49 for the present operating margin
- 0.32 for the gross margin
The net margin for Biolife Solutions Inc stands at -0.46. The total capital return value is set at -0.19. Equity return is now at value -18.93, with -15.40 for asset returns.
Based on Biolife Solutions Inc (BLFS), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -0.44. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -38.9.
Currently, EBITDA for the company is -45.24 million with net debt to EBITDA at -0.15. When we switch over and look at the enterprise to sales, we see a ratio of 5.07. The receivables turnover for the company is 7.68for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.86.
Conclusion
In conclusion, Biolife Solutions Inc (BLFS) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
